
GERMANY - Creathor backs EUR 4m Cevec investment
Creathor Venture Fonds and NRW Bank have co-led a EUR 4m investment in biotechnology company Cevec Pharmaceuticals, alongside a syndicate of private and institutional investors, including the venture capital branch of Sparkasse KoelnBonn and KfW bank's ERP Startfonds.
Cologne-headquartered Cevec, which was founded in 2004, specialises in developing and producing therapeutic proteins and monoclonal antibodies with human glycosylation patterns, which can be used to manufacture complex biopharmaceutical molecules. The company is licensing out its human cell-based expression platform as well as the biological product candidates through partnerships with pharmaceutical and biotech companies.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater